Virenc AB is a pioneering biotech company dedicated to developing innovative antiviral drug technologies. Our unique platform has the potential to combat a wide range of enveloped viruses, opening doors for the development of treatments for multiple viral diseases across different delivery formats.

We are seeking strategic partnerships with pharmaceutical companies to collaborate on product development and licensing opportunities. Our technology is highly versatile and offers a promising avenue for addressing urgent global health challenges. We believe that through collaboration, we can accelerate the development of life-saving antiviral treatments.

Enveloped viruses our technology targets include, but are not limited to:
- Influenza viruses
- Respiratory syncytial virus (RSV)
- Corona viruses (e.g. SARS-CoV-2)
- Mpox (apkoppsvirus)
- Molluscum contagiosum virus (MCV)
- Herpes simplex virus
- Ebola virus
- Zika virus
- Dengue virus
- Varicella-zoster virus

We welcome the opportunity to discuss how Virenc can support your pipeline through the licensing of our technology or by forming a collaborative partnership. Let’s explore how we can jointly develop groundbreaking antiviral treatments that could save lives and improve global health outcomes.